Actively Recruiting
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
Led by The First Affiliated Hospital of Xiamen University · Updated on 2025-09-11
30
Participants Needed
1
Research Sites
285 weeks
Total Duration
On this page
Sponsors
T
The First Affiliated Hospital of Xiamen University
Lead Sponsor
F
Fujian Provincial Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of relapsed and/or refractory AML
CONDITIONS
Official Title
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with relapsed or refractory acute myeloid leukemia confirmed by morphology and immunology
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Life expectancy of at least 3 months
- Adequate kidney function with creatinine clearance of 30 mL/min or higher and serum creatinine 160 µmol/L or lower
- Liver enzymes ALT and AST at or below 3 times the upper limit of normal
- Able to understand and sign the informed consent form
You will not qualify if you...
- Diagnosis of acute promyelocytic leukemia (APL)
- Presence of central nervous system leukemia
- Uncontrolled or significant cardiovascular diseases including severe bradycardia, long QT syndrome, high blood pressure above specified limits, serious ventricular arrhythmias, certain heart blocks without pacemakers, recent heart attacks, advanced heart failure, complete left bundle branch block, or low left ventricular ejection fraction
- Active acute or chronic systemic fungal, bacterial, or viral infection not controlled by treatment
- History of other non-myeloid cancers within 2 years except certain treated skin or in-situ cancers or other solid tumors with no evidence of disease
- Females who are pregnant or breastfeeding
- Mental disorders that interfere with participation
- Previous solid organ transplantation with ongoing graft-versus-host disease or immunosuppression
- Any other condition deemed by the investigator to prevent safe participation in the trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Bing Xu
Xiamen, Fujian, China, 361003
Actively Recruiting
Research Team
B
Bing Xu, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here